- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04852250
Centralized Tumour Board and Secondary Intervention Rate in mCRC
Impact of a Centralized Tumour Board on Secondary Intervention Rate in Patients With RAS Mutant Metastatic Colorectal Cancer After First-line Treatment With FOLFOXIRI Plus Bevacizumab (FIRE-7)
This is a randomised, multicentre observational study in patients suffering from RAS mutant mCRC with primarily unresectable metastases, who are planned to be treated with FOLFOXIRI and bevacizumab or who have already received ≤ four cycles FOLFOXIRI and bevacizumab as first-line treatment of metastatic disease. The patients are randomised in a 1:1 ratio to compare the rate of patients in whom secondary interventions (e.g. resection, ablation) are performed in curative intent when secondary intervention options are assessed by a multidisciplinary centralized tumour board (Arm A) versus when secondary intervention options are not assessed by a multidisciplinary centralized tumour board (Arm B).
All patients evaluated in the study will receive chemotherapy with FOLFOXIRI plus bevacizumab. After this induction/conversion therapy, imaging (CT or MRI) will be performed to evaluate resectability. In Arm A, a multidisciplinary, centralized tumour board will assess options of secondary intervention to be performed in the context of a generally curative treatment approach.
If there are secondary intervention options according to the judgement of the centralized tumour board, they will be listed in their respective sequence and the assessment will be communicated to the participating physician or his/her deputy at the study center. The decision, whether or not any secondary intervention is performed as recommended by the centralized tumour board as well as the kind of interventional procedures is up to the discretion of the treating physicians and surgeons of each patient. Any secondary intervention is recorded.
Evaluating the primary endpoint, the first interventions performed in one organ (e.g. liver) are rated when performed in a generally curative context (e.g. even in the presence of lung metastases that need to be approached in a further intervention).
In Arm B, no centralized tumour board will be integrated in to clinical decision making and patients will be treated according to institutional guidelines.
The number of treatment cycles with FOLFOXIRI and bevacizumab will be according to local clinical routine and medical guidelines, recommended are 8 to 12 cycles FOLFOXIRI in combination with bevacizumab, followed by a maintenance therapy with fluoropyrimidine (FP) plus bevacizumab until progression.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Arndt Stahler, MD
- Phone Number: +49 30 450 613478
- Email: arndt.stahler@charite.de
Study Contact Backup
- Name: Matthias Wolff
- Phone Number: +49 89 4400 72208
- Email: matthias.wolff@med.uni-muenchen.de
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Written informed consent to participate in the study
- Patients ≥ 18 years at the time of signing the informed consent
- Histologically confirmed (in primary tumour or metastasis) UICC stage IV metastatic adenocarcinoma of the colon or rectum (mCRC) with primarily unresectable metastases
- RAS mutant CRC (as determined by local pathology in tissue of primary tumour or metastasis)
- At least one measurable lesion according to RECIST version 1.1 in a CT/MRI scan performed within 28 days prior to start of systemic treatment (first cycle of induction treatment)
- ECOG performance status 0-1
Patients planned to receive chemotherapy with FOLFOXIRI plus bevacizumab as first-line treatment of metastatic disease. De-escalation of FOLFOXIRI to FOLFIRI or FOLFOX is allowed in case of toxicity.
Patients can also be included if they had already received ≤ 4 cycles of induction/conversion therapy with FOLFOXIRI plus bevacizumab (including those patients in whom FOLFOXIRI has been de-escalated to FOLFIRI or FOLFOX due to toxicity) and the first restaging has not been conducted prior to randomization.
- Completion of adjuvant therapy for colorectal cancer > 3 months prior to start of systemic treatment (first cycle of induction treatment).
- Patient's ability for treatment with FOLFOXIRI and bevacizumab according to participating physician's judgement.
Exclusion Criteria:
- Pregnant or breast-feeding women. Females of childbearing potential (FCBPs) who do not practice adequate contraceptive measures as required according to SmPCs of the administered medicinal products.
- Contraindication to intensive chemotherapy with FOLFOXIRI plus bevacizumab
- Contraindications to treatment with 5-FU, oxaliplatin, folinic acid, irinotecan (FOLFOXIRI) and/or bevacizumab according to SmPCs of the administered medicinal products.
- Patients with confirmed cerebral metastasis. In case of clinical suspicion of brain metastasis, a cranial CT or MRI must be performed to rule out brain metastasis before study inclusion.
- Documentation of > 5 lung metastases (however, no limitation for the number of metastases in the liver)
- Isolated distant nodal metastasis, isolated peritoneal metastasis or isolated bone metastasis
- Limited legal capacity
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
FOLFOXIRI plus bevacizumab and centralized tumour board
|
Evaluation of radiologic imaging and general condition by a multidisciplinary expert gremium to recommend either secondary intervention or resection of metastases or continuation of systemic treatment
|
FOLFOXIRI plus bevacizumab but no centralized tumour board
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Secondary intervention rate
Time Frame: 36 months
|
Rate of patients in whom secondary interventions (e.g.
resection, ablation treatment or combination of both) are performed in curative intent
|
36 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Objective response rate (ORR) according to RECIST 1.1
Time Frame: 36 months
|
36 months
|
Progression-free survival (PFS) rate
Time Frame: 6, 12 and 16 months
|
6, 12 and 16 months
|
Overall survival (OS) rate
Time Frame: 6, 12 and 16 months
|
6, 12 and 16 months
|
Type, incidence, relatedness, and severity of adverse events with severity ≥ Grad 3 (severity according to NCI CTCAE version 5.0)
Time Frame: 60 months
|
60 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Volker Heinemann, Prof., Ludwig-Maximilians - University of Munich
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- FIRE-7
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Colorectal Cancer
-
Mayo ClinicCompletedMetastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Metastatic... and other conditionsUnited States
-
Emory UniversityBristol-Myers Squibb; National Cancer Institute (NCI); National Institutes of...Active, not recruitingColorectal Cancer Metastatic | Colorectal Adenocarcinoma | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | Refractory Colorectal Carcinoma | Metastatic Microsatellite Stable Colorectal Carcinoma | Stage IVC Colorectal CancerUnited States
-
Hutchison Medipharma LimitedActive, not recruitingMetastatic Colorectal Cancer | Metastatic Colon CancerUnited States, Spain, Japan, Australia, Austria, Belgium, Czechia, Estonia, France, Germany, Hungary, Italy, Poland, United Kingdom
-
Array Biopharma, now a wholly owned subsidiary...CompletedMetastatic Colorectal Cancer | Advanced Solid Tumors | Advanced or Metastatic Biliary CancerUnited States
-
Zhejiang Cancer HospitalNot yet recruitingMetastatic Colorectal Cancer | Metastatic Colorectal Adenocarcinoma | CRCChina
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingMetastatic Pancreatic Adenocarcinoma | Stage IV Pancreatic Cancer AJCC v6 and v7 | Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Metastatic Gastroesophageal Junction Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Malignant... and other conditionsUnited States
-
AmgenCompletedCancer | Metastatic Colorectal Cancer | Colorectal Cancer | Rectal Cancer | Metastatic Cancer | Colon Cancer
-
Dana-Farber Cancer InstituteAmerican Cancer Society, Inc.Not yet recruitingMetastatic Colorectal Cancer | Colorectal Cancer | Metastatic Colon CancerUnited States
-
AmgenCompletedCancer | Metastatic Colorectal Cancer | Colorectal Cancer | Rectal Cancer | Metastatic Cancer | Colon Cancer | Oncology
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Recurrent Colorectal Carcinoma | Metastatic Malignant Neoplasm in the Liver | Metastatic Colorectal Carcinoma | Metastatic Malignant Neoplasm in the Lung | Resectable Colorectal CarcinomaUnited States
Clinical Trials on Virtual centralized multidisciplinary tumour board
-
Southern Adelaide Local Health NetworkActive, not recruitingPulmonary Nodule, Solitary | Pulmonary Nodule, MultipleAustralia
-
Massachusetts General HospitalTrefler FoundationRecruitingCancer | Breast Cancer | Head and Neck Cancer | Schizophrenia | Lung Cancer | Bipolar Disorder | Gastrointestinal Cancer | Genitourinary Cancer | Severe Major DepressionUnited States
-
Cedars-Sinai Medical CenterWalter Reed National Military Medical CenterCompletedSarcoma | Neoplasms | Lymphoma | Lymphoma, Non-Hodgkin | Leukemia | Cancer | Breast Cancer | Head and Neck Cancer | Gynecologic Cancer | Glioblastoma | Multiple Myeloma | Colorectal Cancer | Hodgkin Lymphoma | Lung Cancer | Bone Cancer | Prostate Cancer | Brain Cancer | Skin Cancer | Pancreas Cancer | Gastrointestinal Cancer | Thyroid... and other conditionsUnited States
-
Bern University of Applied SciencesSwiss Federal Institute of TechnologyCompletedPoor Performance Status | Cognition - OtherSwitzerland
-
Bern University of Applied SciencesGoethe University; Maastricht University Medical Center; Swiss Federal Institute...CompletedMuscle Weakness | Poor Performance StatusSwitzerland
-
University of WashingtonNational Institute of Mental Health (NIMH)RecruitingImplicit BiasUnited States
-
Bern University of Applied SciencesGoethe University; Maastricht University Medical Center; Swiss Federal Institute...CompletedPoor Performance StatusSwitzerland
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI)RecruitingAdvanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States, Puerto Rico